An Open-label Phase II Study of Pembrolizumab in East Asian Patients With Advanced/Metastatic Acral Lentiginous Melanoma
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 16 Feb 2017 Status changed from not yet recruiting to recruiting.
- 23 Nov 2016 Planned initiation date changed from 1 Sep 2016 to 1 Jan 2017.
- 25 Aug 2016 New trial record